Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268526 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT02268526 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT02268526, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
Interventions
- DRUG Placebo
- BIOLOGICAL CSJ148
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2016-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02268526
The ClinicalTrials.gov registry entry for NCT02268526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02268526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02268526 about?
NCT02268526 is a clinical study titled "Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients". This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
What is the current status of trial NCT02268526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2015-06-02. Estimated completion is 2016-12-07.
What interventions are being tested in trial NCT02268526?
The interventions under investigation include: Placebo (DRUG), CSJ148 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02268526?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.